Alhemo is a medicine used to prevent bleeding episodes (prophylaxis) in people aged 12 years and older with haemophilia A or B. People with haemophilia A or B are at risk of bleeding because they lack proteins that help the blood clot (factor VIII for haemophilia A and factor IX for haemophilia B). Alhemo is used: • in people with haemophilia A or B who have developed antibodies (proteins made by the body’s natural defences) called inhibitors that stop factor VIII or factor IX medicines from working properly; • in people who have severe haemophilia A or moderate to severe haemophilia B and have not developed antibodies. Alhemo contains the active substance concizumab.
Therapeutic Indication
### Therapeutic indication Alhemo is indicated for routine prophylaxis of bleeding in patients 12 years of age or more with: • haemophilia A (congenital factor VIII deficiency) with FVIII inhibitors. • severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without FVIII inhibitors. • haemophilia B (congenital factor IX deficiency) with FIX inhibitors. • moderate/severe haemophilia B (congenital factor IX deficiency, FIX ≤ 2%) without FIX inhibitors.
Therapeutic Area (MeSH)
ATC Code
B02BX10
ATC Item
concizumab
Pharmacotherapeutic Group
Antihemorrhagics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| concizumab | N/A | Concizumab |
EMA Name
Alhemo
Medicine Name
Alhemo
Aliases
N/ANo risk management plan link.
